Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 0

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 0
---
Overview 

We are a leading eyecare pharmaceutical
company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market.
We help U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription
pharmaceutical products accessible and affordable to millions of Americans each year. We own commercial rights to one of the largest
portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. We also own
and operate ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical-compounding businesses. 

Branded Ophthalmic Pharmaceuticals 

Over
the past few years, we have invested in broadening our product portfolio of Food and Drug Administration (“FDA”)-approved
products. Our investments in this regard have led to the pursuit and completion of several announced transactions, all of which are focused
on eyecare pharmaceuticals primarily for the U.S. and Canadian markets. We believe that our continued investments in these and other
products will result in our ability to provide more physician prescribers and their patients with access to a complete portfolio of affordable
eyecare pharmaceuticals to address their clinical needs. We own U.S. commercial rights to the following products that we market and sell:

·IHEEZO®
                                            (chloroprocaine hydrochloride ophthalmic gel) 3% a low-viscosity gel indicated for
                                            ocular surface anesthesia.

·VEVYE®
                                            (cyclosporine ophthalmic solution) 0.1%, utilizes a novel water-free vehicle (perfluorobutylpentane)
                                            based on semifluorinated alkanes, indicated for the treatment of the signs and symptoms associated
                                            with dry eye disease.

·TRIESENCE®
                                            (triamcinolone acetonide injectable suspension) 40 mg/ml, a steroid injection for the
                                            treatment of certain ophthalmic diseases and for visualization during vitrectomy.

·VIGAMOX®
                                            (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic
                                            eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

·ILEVRO®
                                            (nepafenac ophthalmic suspension) 0.3%, a non-steroidal,